866-997-4948(US-Canada Toll Free)

Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 50 Pages


GlobalData, the industry analysis specialist, has released its new report, “Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global renal cell carcinoma therapeutics market. The report identifies the key trends shaping and driving the global renal cell carcinoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. 

Most importantly, the report provides valuable insights on the pipeline products within the global renal cell carcinoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimates that the global renal cell carcinoma (RCC) market was valued at $1.3 billion in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 13.9% over the next eight years, to reach $3.8 billion by 2017. 

This high growth forecast is primarily attributed to population growth and high diagnosis rates. In addition, the RCC market will continue to be driven by the strong pipeline landscape of first-in-class drugs with better survival rates, safety and efficacy profiles. 

Scope

The report provides information on the key drivers and challenges of the renal cell carcinoma therapeutics market. Its scope includes:

  • Annualized renal cell carcinoma therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under different mechanisms of actions, which include hemopoietic growth factor, histone deacetylase (HDAC) inhibitors, hepatocyte growth factor/scatter factor (HGF/SF) antagonist, human anti-transforming growth factor, ribonucleotide reductase (RNR) inhibitor, kinesin spindle protein inhibitor, microtubule inhibitor, mitotic inhibitors, and monoclonal antibodies.
  • Analysis of the current and future competition in the global renal cell carcinoma therapeutics market. Key market players covered are Pfizer Inc., Novartis AG, Wilex AG, Antigenics Inc., and Sanofi-Aventis
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the renal cell carcinoma therapeutics therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global renal cell carcinoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global renal cell carcinoma therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global renal cell carcinoma therapeutics market landscape? - Identify, understand and capitalize.
Table of Contents

1 Table of Contents 2

1.1 List of Tables 4
1.2 List of Figures 4

2 Renal Cell Carcinoma Therapeutics: Introduction 5
2.1 Overview 5
2.1.1 Etiology 5
2.1.2 Symptoms 5
2.2 Diagnosis 6
2.3 Clinical Classification and Treatment 6
2.4 Prognosis 7
2.5 GlobalData Pipeline Report Guidance 7

3 Renal Cell Carcinoma Therapeutics: Market Characterization 8
3.1 RCC Therapeutics Market Size 8
3.2 RCC Therapeutics Market Forecast and CAGR 8
3.3 Drivers and Barriers for RCC Therapeutics Market 11
3.3.1 Drivers for RCC Therapeutics Market 11
3.3.2 Barriers for RCC Therapeutics Market 11
3.4 Opportunity and Unmet Need 12
3.5 Key Takeaway 13

4 Renal Cell Carcinoma Therapeutics: Competitive Assessment 14

4.1 Overview 14
4.2 Strategic Competitor Assessment 14
4.3 Product Profile for the Major Marketed Products in RCC Market 15
4.3.1 Avastin (bevacizumab) 15
4.3.2 Sutent (sunitinib malate) 16
4.3.3 Votrient (pazopanib) 17
4.3.4 Afinitor (everolimus) 17
4.3.5 Nexavar (sorafenib) 18
4.3.6 Torisel (temsirolimus) 19
4.4 Major Marketed Products Comparison in RCC Market 20
4.5 Key Takeaway 21

5 Renal Cell Carcinoma Therapeutics: Pipeline Assessment 22
5.1 Overview 22
5.2 Strategic Pipeline Assessment 22
5.2.1 Technology Trends Analytic Framework 22
5.3 RCC Therapeutics Promising Drugs Under Clinical Development 24
5.4 Molecule Profile for Promising Drugs Under Clinical Development 25
5.4.1 Oncophage (vitespen) 25
5.4.2 Axitinib 25
5.4.3 TroVax 26
5.4.4 ANYARA 26
5.4.5 RENCAREX 27
5.5 RCC Therapeutics Market Clinical Pipeline by Therapeutic Class 28
5.5.1 RCC Therapeutics Regulatory Filed Products 29
5.5.2 RCC Therapeutics Phase III Clinical Pipeline 29
5.5.3 RCC Therapeutics Phase II Clinical Pipeline 30
5.5.4 RCC Therapeutics Phase I Clinical Pipeline 32
5.6 Key Takeaway 32

6 Renal Cell Carcinoma Therapeutics: Implications for Future Market Competition 33

7 Renal Cell Carcinoma Therapeutics: Future Players in the RCC Therapeutics Market 34

7.1 Introduction 34
7.2 Pfizer Inc. 34
7.2.1 Company Overview 34
7.2.2 Business Description 35
7.3 Novartis AG 37
7.3.1 Company Overview 37
7.3.2 Business Description 37
7.4 WILEX AG 39
7.4.1 Company Overview 39
7.4.2 Business Description 39
7.5 Antigenics, Inc 40
7.5.1 Company Overview 40
7.5.2 Business Description 40
7.6 Sanofi-Aventis 41
7.6.1 Company Overview 41
7.6.2 Business Description 41

8 Renal Cell Carcinoma Therapeutics: Appendix 44
8.1 Definitions 44
8.2 Acronyms 44
8.3 Research Methodology 45
8.3.1 Coverage 46
8.3.2 Secondary Research 46
8.3.3 Forecasting 46
8.3.4 Primary Research 49
8.3.5 Expert Panel Validation 49
8.4 Contact Us 49
8.5 Disclaimer 49
8.6 Sources 50

List of Table


Table 1: Clinical Classification and Treatment 6
Table 2: TNM Staging of Renal Cell Cancer and Survival 7
Table 3: RCC Therapeutics, Global, Market Revenue ($m), 20012009 9
Table 4: RCC Therapeutics, Global, Market Forecasts ($bn), 20092017 10
Table 5: RCC Therapeutics, Marketed Products Comparison, 2010 20
Table 6: RCC Therapeutics, Most Promising Drugs Under Clinical Development, 2010 24
Table 7: RCC Therapeutics, Other MOAs (30%) 28
Table 8: RCC Therapeutics, Regulatory Filed Products, 2010 29
Table 9: RCC Therapeutics, Phase III Clinical Pipeline, 2010 29
Table 10: RCC Therapeutics, Phase II Clinical Pipeline, 2010 30
Table 11: RCC Therapeutics, Phase I Clinical Pipeline, 2010 32
Table 12: Pfizer Inc, Oncology Pipeline Products, 2010 36
Table 13: Pfizer Inc, RCC Pipeline Products, 2010 37
Table 14: Novartis AG, Oncology Pipeline Products, 2010 38
Table 15: Novartis AG, RCC Pipeline Products, 2010 38
Table 16: WILEX AG, Oncology Pipeline Products, 2010 39
Table 17: WILEX AG, RCC Pipeline Products, 2010 39
Table 18: Antigenics Inc, Oncology Pipeline Products, 2010 40
Table 19: Antigenics, Inc, RCC Pipeline Products, 2010 41
Table 20: Sanofi-aventis, Oncology Pipeline Products, 2010 43
Table 21: Sanofi-aventis, RCC Pipeline Products, 2010 43

List of Chart


Figure 1: RCC Therapeutics, Global, Market Revenue ($m), 20012009 9
Figure 2: RCC Therapeutics, Global, Market Forecasts ($m), 20092017 10
Figure 3: RCC Therapeutics, Opportunity and Unmet Need, 2010 12
Figure 4: RCC Therapeutics, Strategic Competitor Assessment of Major Marketed Products, 2010 14
Figure 5: Technology Trends Analytic Framework of the RCC Therapeutics Pipeline, 2010 22
Figure 6: Technology Trends Analytic Framework of the RCC Therapeutics Pipeline Description, 2010 23
Figure 7: RCC Therapeutics, Clinical Pipeline by Mechanism of Action, 2010 28
Figure 8: RCC Therapeutics, Pipeline by Phase of Clinical Development, 2010 29
Figure 9: RCC Therapeutics, Implications for Future Market Competition, 2010 33
Figure 10: RCC Therapeutics, Pipeline by Company, 2010 34
Figure 11: GlobalData Market Forecasting Model 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *